Clinical Trial Update: T-cell Based Immunotherapy for Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of T-cell based immunotherapy for head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: Inge Marie Svane | Conditions: Squamous Cell Carcinoma, Head and Neck Cancer | Phase 1 | Status: WITHDRAWN